Media
Press Releases
HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative
HDT bio's Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ -- HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies, is proud...
HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68
Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the...
HDT Bio to Participate in World Vaccine Congress West Coast 2023
SEATTLE, Nov. 16, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa Clara,...
HDT Bio to Present Novel Vaccine Technologies for Cancer Immunoprevention at SITC 2023 Annual Meeting
SEATTLE, Oct. 31, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that Dr. Steven Reed, Chief Executive Officer of HDT Bio, will present at the...
HDT Bio Receives $1 Million Award from BLUE KNIGHT™ Resident QuickFire Challenge in Support of Project NextGen
Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate HDT-201 investigated as pre-exposure or post exposure prophylactic in high-risk situations SEATTLE, Oct. 4, 2023...
HDT Bio Announces Appointment of Key Clinical Oncology Experts
Scientific Advisors to provide expertise and counsel on the clinical development of its RNA-based oncology pipeline candidates HDT Bio announces esteemed medical experts Dr. Charles Cobbs of the Swedish Neuroscience Institute and Dr. Elizabeth Jaffee of Johns Hopkins...
HDT Bio Publishes Peer-Reviewed Study Demonstrating Advantages of repRNA and LION™ Technology
LION™-formulated repRNA vaccination exhibited a significant safety profile, along with enhanced efficacy and biodistribution response when compared to lipid nanoparticle (LNP)-formulated repRNA vaccines in mice Study findings, published in the peer-reviewed...
HDT Bio Publishes Peer-Reviewed Preclinical Study Demonstrating Robust Immunological Response in Mothers and Newborns Following repRNA/LION™ Vaccination
LION-formulated, repRNA vaccination against HIV-1 and ZIKV successfully produced a robust immunological response in pregnant rabbits; maternal antibodies were transferred in utero to newborn kits Findings published in the peer-reviewed journal Molecular Therapy...
HDT Bio to Develop RNA Cancer Vaccines and Treatments with South Africa’s Pan African Cancer Research Institute (PACRI)
Goal ‘to change the cancer research narrative in Africa’ by applying HDT Bio’s advanced technology to help reduce inequalities in health care PRETORIA, SOUTH AFRICA and SEATTLE, WA (January 30, 2023) – HDT Bio Corp., a developer of immunotherapies for infectious...
UTMB and HDT Bio awarded prototype project funding worth up to $87.4M from the U.S. government to develop saRNA vaccine technology
UTMB will collaborate with HDT Bio Corp. and the National Institute of Allergy and Infectious Diseases’ Rocky Mountain Labs to develop vaccines against Crimean-Congo hemorrhagic fever virus (CCHFV) and Nipah virus (NiV) The 5-year $59M prototype project will develop...
In the News
Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
Click here to view article
Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
Click here to view article
Bioprocess Online Live: Capital, Manufacturing Market Acceptance Of Therapeutic Cancer Vaccines
Click here to view article
Bioprocess Online: Capital, Manufacturing Market Acceptance Of Therapeutic Cancer Vaccines
Click here to view article
Bioprocess Online Live: Why Therapeutic Cancer Vaccines Haven’t Worked To Date
Click here to view article
Bioprocess Online: Why Therapeutic Cancer Vaccines Haven’t Worked To Date
Click here to view article
Bioprocess Online Live: Why The Cancer Vaccine Concept Is En Vogue Again
Click here to view article
Bioprocess Online: Why The Cancer Vaccine Concept Is En Vogue Again
Click here to view article
Law360: Indian Pharma Co. Can’t Get Fees In $950M COVID Vax Suit
Click here to view article
Bioprocess Online Live: Where Therapeutic Cancer Vaccines Go Next
Click here to view article